知名医美巨头涉嫌严重造假？回应来了

Core Viewpoint - The company "可复美" (Kefumei) strongly denies allegations regarding the lack of recombinant collagen protein in its products, asserting compliance with relevant regulations and standards [1][2][3]. Group 1: Company Response to Allegations - Kefumei refutes claims of serious fraud and emphasizes that all product development and production adhere to the "Cosmetics Supervision and Administration Regulations" and related laws [1]. - The company confirms that all products undergo a three-tier verification system, including raw material checks, production quality control, and finished product testing, ensuring product safety and reliability [1]. - Initial internal testing showed collagen protein content exceeding 0.1%, contradicting the alleged 0.0177% [1][2]. Group 2: Regulatory Compliance and Standards - According to the National Medical Products Administration's "Cosmetics Labeling Management Measures," ingredients must be listed in descending order based on their content, with those below 0.1% labeled as "other trace ingredients" [2]. - The product in question has a soluble collagen content greater than 0.1%, thus it is listed as a main ingredient, further disputing the claims of low content [2]. Group 3: Third-Party Testing and Industry Standards - To address consumer concerns, Kefumei has engaged multiple authoritative third-party testing agencies to conduct further testing, which will be reported once available [3]. - The company notes that the testing methods used by the accusers are not recognized by industry standards, rendering their results unreliable [3]. - The National Medical Products Administration is working on establishing industry standards for recombinant collagen protein testing, and Kefumei is actively participating in this initiative [3]. Group 4: Company Performance - Kefumei, a brand under the publicly listed company 巨子生物 (Giant Bio), reported sales revenue exceeding 4.5 billion yuan, marking a 62.9% year-on-year increase [4]. - As of May 23, the market capitalization of Giant Bio exceeded 80 billion Hong Kong dollars [4].